

SENATE BILL 384

C8

3lr1805
CF HB 726

By: **Senators Pugh, Astle, Benson, Conway, Currie, DeGrange, Dyson, Forehand, Garagiola, Getty, Glassman, Jacobs, Jones–Rodwell, Kelley, King, Kittleman, Klausmeier, Madaleno, Mathias, McFadden, Montgomery, Muse, Peters, Raskin, Robey, and Stone**

Introduced and read first time: January 25, 2013

Assigned to: Finance

Committee Report: Favorable with amendments

Senate action: Adopted

Read second time: February 25, 2013

CHAPTER _____

1 AN ACT concerning

2 **Economic Development – Sickle Cell Disease Research Program**

3 FOR the purpose of establishing the Sickle Cell Disease Research Program to be
4 administered by the Maryland Technology Development Corporation to provide
5 grants for certain sickle cell disease research projects; establishing the purposes
6 of the Program; establishing the Sickle Cell Disease Research Fund in the
7 Corporation; providing for the purpose and composition of the Fund; requiring
8 the Executive Director of the Corporation or the Executive Director’s designee to
9 administer the Fund; requiring the State Treasurer to invest money in the
10 Fund; providing that earnings of the Fund shall be credited to the Fund;
11 establishing certain types of grants to be awarded under the Program; requiring
12 the Corporation to adopt certain regulations; requiring the Corporation to
13 include certain information in a certain report to the Governor and General
14 Assembly; exempting the Fund from a certain provision of law requiring
15 interest on State money in special funds to accrue to the General Fund of the
16 State; defining certain terms; and generally relating to the creation of a
17 program for sickle cell disease research.

18 BY adding to

19 Article – Economic Development

20 Section 10–463 through 10–468 to be under the new part “Part VI. Sickle Cell
21 Disease Research Program”

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.

Underlining indicates amendments to bill.

~~Strike out~~ indicates matter stricken from the bill by amendment or deleted from the law by amendment.



1 Annotated Code of Maryland
2 (2008 Volume and 2012 Supplement)

3 BY repealing and reenacting, with amendments,
4 Article – State Finance and Procurement
5 Section 6–226(a)(2)(ii)69. and 70.
6 Annotated Code of Maryland
7 (2009 Replacement Volume and 2012 Supplement)

8 BY adding to
9 Article – State Finance and Procurement
10 Section 6–226(a)(2)(ii)71.
11 Annotated Code of Maryland
12 (2009 Replacement Volume and 2012 Supplement)

13 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF
14 MARYLAND, That the Laws of Maryland read as follows:

15 **Article – Economic Development**

16 **10–461. RESERVED.**

17 **10–462. RESERVED.**

18 **PART VI. SICKLE CELL DISEASE RESEARCH PROGRAM.**

19 **10–463.**

20 (A) IN THIS PART THE FOLLOWING WORDS HAVE THE MEANINGS
21 INDICATED.

22 (B) “FUND” MEANS THE SICKLE CELL DISEASE RESEARCH FUND
23 ESTABLISHED UNDER § 10–465 OF THIS PART.

24 (C) “PROGRAM” MEANS THE SICKLE CELL DISEASE RESEARCH
25 PROGRAM ESTABLISHED UNDER § 10–464 OF THIS PART.

26 **10–464.**

27 (A) **THERE IS A SICKLE CELL DISEASE RESEARCH PROGRAM.**

28 (B) **THE PURPOSE OF THE PROGRAM IS TO:**

29 (1) **PROMOTE MILESTONE–DRIVEN TRANSLATIONAL RESEARCH**
30 **USING BONE MARROW AND UMBILICAL CORD BLOOD TO DEVELOP TREATMENTS**
31 **AND CURES FOR SICKLE CELL DISEASE; AND**

1 **(2) ESTABLISH THE STATE AS A KEY LOCATION FOR SICKLE CELL**
2 **DISEASE RESEARCH AND TREATMENT.**

3 **(C) THE CORPORATION SHALL ADMINISTER THE PROGRAM.**

4 **10-465.**

5 **(A) THERE IS A SICKLE CELL DISEASE RESEARCH FUND IN THE**
6 **CORPORATION.**

7 **(B) THE PURPOSE OF THE FUND IS TO PROVIDE GRANTS AND LOANS TO**
8 **PUBLIC AND PRIVATE ENTITIES IN THE STATE TO DEVELOP TREATMENTS AND**
9 **CURES FOR SICKLE CELL DISEASE ~~USING BONE MARROW AND UMBILICAL CORD~~**
10 **BLOOD.**

11 **(C) (1) THE FUND IS A SPECIAL, NONLAPSING FUND THAT IS NOT**
12 **SUBJECT TO § 7-302 OF THE STATE FINANCE AND PROCUREMENT ARTICLE.**

13 **(2) THE STATE TREASURER SHALL HOLD THE FUND**
14 **SEPARATELY, AND THE COMPTROLLER SHALL ACCOUNT FOR THE FUND.**

15 **(D) THE FUND CONSISTS OF:**

16 **(1) MONEY APPROPRIATED IN THE STATE BUDGET TO THE FUND;**
17 **AND**

18 **(2) ANY OTHER MONEY FROM ANY OTHER SOURCE ACCEPTED FOR**
19 **THE BENEFIT OF THE FUND.**

20 **(E) THE EXECUTIVE DIRECTOR OF THE CORPORATION, OR THE**
21 **EXECUTIVE DIRECTOR'S DESIGNEE, SHALL ADMINISTER THE FUND IN**
22 **ACCORDANCE WITH THIS PART AND OTHER APPLICABLE LAW.**

23 **(F) THE FUND SHALL BE USED TO COVER THE COSTS OF THE**
24 **PROGRAM, INCLUDING ANY GRANTS AND LOANS THAT ARE AWARDED TO**
25 **ELIGIBLE RECIPIENTS.**

26 **(G) (1) THE STATE TREASURER SHALL INVEST THE MONEY OF THE**
27 **FUND IN THE SAME MANNER AS OTHER STATE MONEY MAY BE INVESTED.**

28 **(2) ANY INVESTMENT EARNINGS OF THE FUND SHALL BE**
29 **CREDITED TO THE FUND.**

1 **(H) (1) THE GOVERNOR MAY INCLUDE IN THE STATE BUDGET BILL**
2 **FOR EACH FISCAL YEAR AN APPROPRIATION TO THE FUND.**

3 **(2) EXPENDITURES FROM THE FUND MAY BE MADE ONLY IN**
4 **ACCORDANCE WITH AN APPROPRIATION BY THE GENERAL ASSEMBLY IN THE**
5 **STATE BUDGET OR BY AN APPROVED BUDGET AMENDMENT.**

6 **10-466.**

7 **WITHIN THE SICKLE CELL DISEASE RESEARCH PROGRAM, SUBJECT TO**
8 **AVAILABLE FUNDING, THE CORPORATION SHALL AWARD CAPITAL AND**
9 **OPERATING GRANTS FROM THE FUND TO PUBLIC OR PRIVATE SECTOR ENTITIES**
10 **IN THE STATE TO DEVELOP ~~A CURE~~ TREATMENTS AND CURES FOR SICKLE CELL**
11 **DISEASE THAT WILL BE WIDELY AVAILABLE TO A MAJORITY OF INDIVIDUALS**
12 **DIAGNOSED WITH THE DISEASE.**

13 **10-467.**

14 **(A) THE CORPORATION SHALL ADOPT REGULATIONS TO ESTABLISH:**

15 **(1) A COMPETITIVE APPLICATION PROCESS; AND**

16 **(2) CRITERIA AND PROCEDURES FOR AWARDING GRANTS FROM**
17 **THE FUND TO ELIGIBLE RECIPIENTS.**

18 **(B) (1) IN ACCORDANCE WITH THIS PART, ALL PUBLIC AND PRIVATE**
19 **ENTITIES IN THE STATE MAY BE ELIGIBLE RECIPIENTS OF GRANTS.**

20 **(2) PRIORITY FOR THE AWARD OF ANY GRANT SHALL BE GIVEN**
21 **TO THOSE PROJECTS THAT:**

22 **(I) USE BONE MARROW OR UMBILICAL CORD BLOOD; AND**

23 **(II) ARE MOST LIKELY TO RESULT IN A TREATMENT OR**
24 **CURE FOR SICKLE CELL DISEASE THAT WILL BE WIDELY AVAILABLE TO A**
25 **MAJORITY OF INDIVIDUALS DIAGNOSED WITH THE DISEASE.**

26 **10-468.**

27 **THE CORPORATION SHALL INCLUDE, AS PART OF ITS ANNUAL REPORT TO**
28 **THE GOVERNOR AND GENERAL ASSEMBLY UNDER § 10-415 OF THIS SUBTITLE,**
29 **A DETAILED DESCRIPTION OF THE GRANTS AWARDED UNDER THIS PART.**

30 **Article – State Finance and Procurement**

1 6-226.

2 (a) (2) (ii) The provisions of subparagraph (i) of this paragraph do not
3 apply to the following funds:

4 69. the Maryland Legal Services Corporation Fund; [and]

5 70. Mortgage Loan Servicing Practices Settlement Fund;

6 AND

7 71. THE SICKLE CELL DISEASE RESEARCH FUND.

8 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect
9 October 1, 2013.

Approved:

Governor.

President of the Senate.

Speaker of the House of Delegates.